<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Extracted Document</title>
    <style>
        body { font-family: Arial, sans-serif; max-width: 900px; margin: 0 auto; padding: 20px; }
        h1, h2, h3 { color: #333; }
        .page { margin-bottom: 50px; border-bottom: 2px solid #ccc; padding-bottom: 30px; }
        .title { font-size: 1.3em; font-weight: bold; margin: 20px 0; }
        .text { margin: 15px 0; line-height: 1.6; }
        .figure { margin: 20px 0; text-align: center; }
        .figure img { max-width: 100%; height: auto; border: 1px solid #ddd; }
        .figure-caption { font-style: italic; color: #666; margin-top: 10px; }
        .metadata { background: #f5f5f5; padding: 15px; margin-top: 30px; }
    </style>
</head>
<body>

<h1>Extracted Document</h1>
<p><strong>Source:</strong> data/clinical_files/CDC Influenza vaccines.pdf</p>
<p><strong>Total Pages:</strong> 2</p>
<hr>
<div class="page">
<h2>Page 1</h2>
<div class="title">TABLE. Influenza vaccines — United States, 2023–
24 influenza season*</div>
<div class="figure">
<img src="figures/figure_p1_46d529d3.png" alt="[FIGURE 2 - See figure_p1_46d529d3.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 2 - See figure_p1_46d529d3.png]</div>
</div>
<div class="text">aIIV4 (standard-dose, egg-based  vaccine with MF59 adjuvant)<br>†</div>
</div>
<div class="page">
<h2>Page 2</h2>
<div class="figure">
<img src="figures/figure_p2_e7c86f4e.png" alt="[FIGURE 1 - See figure_p2_e7c86f4e.png]" style="max-width: 800px;">
<div class="figure-caption">[FIGURE 1 - See figure_p2_e7c86f4e.png]</div>
</div>
<div class="text">Abbreviations: ACIP = Advisory Committee on Immunization Practices; HA = hemagglutinin; IIV4 = inactivated influenza<br>vaccine, quadrivalent; IM = intramuscular; LAIV4 = live attenuated influenza vaccine, quadrivalent; MDV = multidose vial;<br>PFS = prefilled syringe; RIV4 = recombinant influenza vaccine, quadrivalent; SDV = single-dose vial.</div>
<div class="text">* Manufacturer package inserts and updated CDC and ACIP guidance should be consulted for additional information<br>concerning, but not limited to, indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed<br>vaccines are available at https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states<br>.<br>Availability and characteristics of specific products and presentations might change or differ from what is described in this<br>table and in the text of this report.<br></div>
<div class="text">Although a history of severe allergic reaction (e.g., anaphylaxis) to egg is a labeled contraindication to the use of egg-based<br>IIV4s and LAIV4, ACIP recommends that all persons aged ≥6 months with egg allergy should receive influenza vaccine and<br>that any influenza vaccine (egg based or nonegg based) that is otherwise appropriate for the recipient’s age and health<br>status can be used (see Persons with a History of Egg Allergy).<br>†</div>
<div class="text">The approved dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for<br>persons aged ≥3 years. However, 0.25-mL prefilled syringes are no longer available. For children aged 6 through 35<br>months, a 0.25-mL dose must be obtained from a multidose vial.<br>§</div>
<div class="text">IM-administered influenza vaccines should be administered by needle and syringe only, with the exception of the MDV<br>presentation of Afluria Quadrivalent, which may alternatively be given by the PharmaJet Stratis jet injector for persons ag<br>18 through 64 years only. For older children and adults, the recommended site for IM influenza vaccination is the deltoid<br>muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Additional specific<br>guidance regarding site selection and needle length for IM administration is available in the General Best Practice<br>Guidelines for Immunization available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.<br>¶</div>
<div class="title">** Not applicable.</div>
<div class="title">Fluzone Quadrivalent is approved for children aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however,
0.25-mL prefilled syringes are no longer available. If a prefilled syringe of Fluzone Quadrivalent is used for a child in this
age group, the dose volume will be 0.5 mL per dose.
†
Last Reviewed: August 24, 2023</div>
</div>
<div class="metadata">
<h3>Extraction Metadata</h3>
<p>Text blocks: 9</p>
<p>Figures/Tables: 2</p>
</div>

</body>
</html>
